Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?

Hims Hers Health Inc. (NYSE:HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.

Benzinga

Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

Benzinga

Benzinga Bulls And Bears: Celestica, Carvana, Novo Nordisk — And Fed Holds Rates Despite Trump Pressure

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Will Hims & Hers Fall Along With Novo Nordisk?

Novo Nordisk shares are trading as low as 35% of their 52-week highs, making Hims & Hers investors nervous whether a selloff is coming.

MarketBeat

Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients

The U.S. Food and Drug Administration approved on Friday, the Novo Nordisk A/S (NYSE:NVO) Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in patients 12 years of age and older with hemophilia A or B without inhibitors.

Benzinga

Companies explore other uses for popular weight loss injections

IN FULL

The Independent UK

Should You Buy the Post-Earnings Plunge in Novo Nordisk Stock or Stay Far, Far Away?

Novo Nordisk is a healthcare stock that is down 50% in 2025. Is NVO stock undervalued at current levels or can it move lower over the next 12 months?

Barchart

Read news from The Economist, FT, and more,
with one subscription

Weight loss drugs could soon be used to treat these seven other health conditions

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success

The Independent UK

Hims & Hers Stock Up, Nearing All-Time High As Weight-Loss Giants Stumble

Shares of telehealth company Hims Hers Health Inc (NYSE:HIMS) are up Thursday afternoon, and at one point, approached a new all-time high. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.

Benzinga

Novo Nordisk Stock Hits New 52-Week Low Amid Profit Warning: What Investors Need To Know

Shares of Novo Nordisk A/S (NYSE:NVO) are trading lower Wednesday morning, extending a dramatic sell-off from Tuesday’s session. Here’s what investors need to know.

Benzinga

Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says 'Could've Played Out VERY Differently If They Had Embraced $HIMS'

Weight-loss drugmaker Novo Nordisk A/S (NYSE:NVO)’s technical chart is displaying a largely bearish trend amid a profit warning issued by the company tied to its blockbuster obesity drug Wegovy. However, this expert believes that the Danish pharmaceutical giant could have avoided some trouble if it hadn’t ended its partnership with…

Benzinga

UnitedHealth Stock Drags on Dow: Stock Market Today

Corporate earnings have dominated Wall Street's attention this week, but that changes on Wednesday.

Kiplinger

What's Going On With Eli Lilly Stock On Tuesday?

Eli Lilly and Co. (NYSE:LLY) stock is trading lower on Tuesday after its weight loss drug rival, Novo Nordisk A/S (NYSE:NVO), trimmed its 2025 financial outlook.

Benzinga

Novo Nordisk Cuts Earning Forecasts Again, Names New CEO

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its earning forecasts again as it unveiled a new chief executive to tackle "recent market challenges".

International Business Times

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

Ozempic and Wegovy maker Novo Nordisk sees shares tumble on profit alert

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Euronews

Novo Nordisk shares plummet over 20% on weight-loss drug sale slump

The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.

Benzinga

Novo Nordisk Implodes After Wegovy Warning—Is The Weight-Loss Bubble Bursting?

Novo Nordisk A/S (NYSE:NVO) suffered its worst trading session on record Tuesday, plunging as much as 25% in European markets after issuing a surprise profit warning tied to its blockbuster obesity drug Wegovy and appointing a new CEO.

Barchart

Here’s What Happened the Last Time Novo Nordisk Stock Was This Oversold

NVO stock is plunging lower in premarket trading after slashing its guidance for 2025 again.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Trump’s 15% tariff on medicines will harm patients, say EU drugmakers

Trade group says levy will reduce access, disrupt supply chains and cut R&D

Benzinga

Ozempic And Wegovy Maker Cuts Outlook In Surprise Move, Picks New CEO

Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment Ozempic, experienced a significant downturn on Tuesday following the company’s decision to trim its 2025 financial outlook.

The Independent UK

Weight-loss jab Wegovy sees another prescription boost after ban on copycats

Novo CEO ousted in May, in place until successor named

Benzinga

Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China

In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY) Zepbound from flooding the market.

Benzinga

Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case

The Novo Nordisk A/S (NYSE:NVO) attempt to block Mylan Pharmaceuticals from launching a generic version of its weight-loss drug Wegovy hit a major obstacle as the court ruled in Mylan's favor on key infringement claims related to U.S. Patent No. 9,764,003.

Benzinga

What's Going On With Hims & Hers Stock Wednesday?

Hims Hers Health, Inc. (NYSE:HIMS) shares are trading 16% higher Wednesday, adding to gains of more than 35% over the past month. Here’s a look at what’s going on.

Benzinga

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'

As the Donald Trump administration plans up to 200% tariffs on pharmaceutical companies, Emily Field, head of European pharma research at Barclays, has said that it’s hard to predict which firm would be affected the most by these tariffs, except for Novo Nordisk A/S (NYSE:NVO).

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.